Compare ACGL & NTRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACGL | NTRA |
|---|---|---|
| Founded | 2001 | 2003 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 28.0B |
| IPO Year | N/A | 2015 |
| Metric | ACGL | NTRA |
|---|---|---|
| Price | $93.40 | $181.80 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 14 |
| Target Price | $108.79 | ★ $259.07 |
| AVG Volume (30 Days) | ★ 1.4M | 1.1M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.65 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $210,939,000.00 |
| Revenue This Year | N/A | $18.16 |
| Revenue Next Year | $3.72 | $20.00 |
| P/E Ratio | $8.45 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $82.45 | $125.38 |
| 52 Week High | $102.90 | $256.36 |
| Indicator | ACGL | NTRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.72 | 34.86 |
| Support Level | $90.62 | $157.43 |
| Resistance Level | $94.33 | $181.85 |
| Average True Range (ATR) | 1.48 | 7.08 |
| MACD | -0.07 | -0.15 |
| Stochastic Oscillator | 38.96 | 1.62 |
Arch Capital Group Ltd is a Bermuda company that writes insurance and reinsurance with operations in the United States, Canada, Europe, Australia, and the United Kingdom. The business operates through three underwriting segments: insurance, reinsurance, and mortgage. The insurance segment provides specialty risk solutions to clients across various industries. The reinsurance segment provides reinsurance services which cover property catastrophe, property, liability, marine, aviation and space, trade credit and surety, agriculture, accident, life and health, and political risk. The mortgage business provides risk management and risk financing products to the mortgage insurance sectors through platforms in the U.S., Europe and Bermuda.
Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.